The real-world effectiveness of automated insulin suspension features was evaluated from patients with type 1 diabetes (T1D) in the UK. Automated insulin suspension has been shown to reduce the burden of hypoglycaemia for patients with T1D in clinical studies.
Materials and methods
We retrospectively analysed anonymised data voluntarily uploaded to CareLink™ software from patients using: sensor augmented pump without insulin suspension feature enabled (SAP), SAP with Low Glucose Suspend feature enabled (SAP+LGS) or SAP with predictive insulin suspension feature enabled (SAP+SmartGuard™) from February 2016 to June 2018. Inclusion criteria were at least 15 days of sensor data per patient with ≥70% wear time from the first day of sensor wear within the 2-year observation period. Where patients changed suspend features between SAP, LGS or SmartGuard™, within patient comparisons were made for time in range and time in hypoglycaemia.
In the total study population (n=920), patients used the system for a mean of 219 day. Patients spent less time in Sensor Glucose values ≤3 mmol/l and ≤3.9 mmol/l when using SAP+SmartGuard™ than when using SAP+LGS or SAP only. During the study duration 187 patients changed groups. Within the same patient, there was a reduction not only in time but also in events <3 mmol/l and <3.9 mmol/l when patients moved from SAP to LGS and when moved from LGS to SmartGuard™ (Table1).
This analysis shows that sensor-augmented-pumps with automated insulin suspension technology reduced the frequency and duration of hypoglycaemic events compared to sensor-augmented-pumps with no suspension.